The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN

Simone Olgiati1, Okan Doğu2, Zeynep Tufekcioglu3

  • 1Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.

Abstract

Insights

The C19orf12 p.Thr11Met mutation is common in Turkish adults with mitochondrial membrane protein associated neurodegeneration (MPAN). This finding aids in diagnosing MPAN in individuals of Turkish descent.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Mitochondrial membrane protein associated neurodegeneration (MPAN) is a rare, inherited neurodegenerative disorder.
  • Mutations in the C19orf12 gene are a known cause of MPAN, a type of neurodegeneration with brain iron accumulation (NBIA).
  • Limited data exists on C19orf12 mutations, especially in adult-onset cases.

Purpose of the Study:

  • To investigate the frequency of C19orf12 mutations in Turkish adults with idiopathic NBIA.
  • To characterize the clinical and genetic features of MPAN in this population.

Main Methods:

  • Sequencing of the C19orf12 gene in 15 Turkish adult NBIA probands.
  • Haplotype analysis in families with identified C19orf12 mutations.
  • Standardized clinical data collection.

Main Results:

  • The homozygous c.32C>T mutation in C19orf12 (p.Thr11Met) was identified in 60% of probands.
  • This mutation co-segregated with the disease in affected relatives.
  • Clinical presentation included adult onset (mean age 24.5 years), parkinsonism, pyramidal signs, psychiatric issues, cognitive decline, and neuropathy.
  • MRI revealed characteristic bilateral hypointensities in globus pallidus and substantia nigra.

Conclusions:

  • The C19orf12 p.Thr11Met mutation is a frequent cause of MPAN among adult Turkish patients.
  • These findings are crucial for the genetic diagnosis of MPAN in individuals of Turkish origin.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
47
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
158.6K
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
21.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56